Design and Synthesis of 8-Hydroxy-[1,6]Naphthyridines as Novel Inhibitors of HIV-1 Integrase in Vitro and in Infected Cells
摘要:
Naphthyridine 7 inhibits the strand transfer of the integration process catalyzed by integrase with an IC50 of 10 nM and inhibits 95% of the spread of HIV-1 infection in cell culture at 0.39 muM. It does not exhibit cytotoxicity in cell culture at less than or equal to 12.5 muM and shows a good pharmacokinetic profile when dosed orally to rats. The antiviral activity of 7 and its effect on integration were confirmed using viruses with specific integrase mutations.
Feedstocks to Pharmacophores: Cu-Catalyzed Oxidative Arylation of Inexpensive Alkylarenes Enabling Direct Access to Diarylalkanes
作者:Aristidis Vasilopoulos、Susan L. Zultanski、Shannon S. Stahl
DOI:10.1021/jacs.7b03387
日期:2017.6.14
A Cu-catalyzed method has been identified for selective oxidative arylation of benzylic C-H bonds with arylboronic esters. The resulting 1,1-diarylalkanes are accessed directly from inexpensive alkylarenes containing primary and secondary benzylic C-H bonds, such as toluene or ethylbenzene. All catalyst components are commercially available at low cost, and the arylboronic esters are either commercially
已经确定了一种 Cu 催化的方法,用于苄基 CH 键与芳基硼酸酯的选择性氧化芳基化。所得的 1,1-二芳基烷烃可直接从含有伯和仲苄基 CH 键的廉价烷基芳烃(如甲苯或乙苯)中获得。所有催化剂组分均可以低成本商购获得,并且芳基硼酸酯可商购获得或容易从商购硼酸获得。强调了这些方法在药物化学应用中的潜在效用。
AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS
申请人:Merck & Co., Inc.
公开号:EP1333831A2
公开(公告)日:2003-08-13
[EN] AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS<br/>[FR] AZA- ET POLYAZA-NAPHTALENYL CETONES UTILES EN TANT QU'INHIBITEURS DE L'INTEGRASE DU VIH
申请人:MERCK & CO INC
公开号:WO2002036734A2
公开(公告)日:2002-05-10
Certain aza- and polyaza-naphthalenyl ketones including certain quinolinyl and naphthyridinyl ketones are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment or the delay in the onset of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.